Theravance Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Theravance Biopharma

04/11/2023 03:05

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results 
    * The George Town Grand Cayman-based  company is expected to
report  a 20.5% increase in revenue to $15.002 million from
$12.45 million a year ago, according to the mean estimate from 4
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Theravance
Biopharma Inc
is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $14​, above​ its last closing price of $9.85.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.22       -0.21      -0.28     Missed  -33.3
 Mar. 31 2023  -0.25       -0.25      -0.35     Missed  -42.1
 Dec. 31 2022  -0.17       -0.17      -0.15     Beat    13​
 Sep. 30 2022  -0.21       -0.18      -0.21     Missed  -15.1
 ​​Jun.        0.09        0.11       -0.09     Missed  -182.6
 30 2022                                                
 Mar. 31 2022  -0.11       -0.11      -0.22     Missed  -107.5
                                                        ​
 Dec. 31 2021  -0.32       -0.33      -0.43     Missed  -29.7
 Sep. 30 2021  -0.56       -0.56      -0.48     Beat    14.1
 This summary was machine generated November 4 at 03:05 GMT.  All
figures in US dollars  unless otherwise stated